Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adoptive Immunotherapy for Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell

NCT03910842 is registered in ClinicalTrials.gov with Timmune Biotech Inc. as lead sponsor.

NCT NCT03910842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03910842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adoptive Immunotherapy for Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell
Lead sponsor
Timmune Biotech Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
March 21, 2019
Completion date
October 15, 2022
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, non-hodgkin lymphoma of intestine